Journal
CLINICAL & TRANSLATIONAL IMMUNOLOGY
Volume 2, Issue -, Pages -Publisher
WILEY
DOI: 10.1038/cti.2013.5
Keywords
melanoma; immunity; immunotherapy; checkpoint blockade; tumor-infiltrating lymphocytes
Categories
Funding
- Bristol-Myers Squibb
Ask authors/readers for more resources
The strategy of immune modulation for the treatment of cancer is being refined with the introduction of multiple new therapeutic agents into the clinic. Melanoma is a disease where many of these agents have demonstrated efficacy. The mechanisms of action of these agents exploit the counter-regulatory mechanisms of the immune response. However, these agents are also associated with immune-related adverse events (IRAEs), which represent tissue-specific inflammatory responses. These IRAEs highlight the delicate balance of immunologic homeostasis and, with some interventions, may occur more frequently in patients who sustain a therapeutic response. This review will discuss melanoma immunogenicity and immunotherapy. Furthermore, the spectrum and distinction between a reversible immune adverse event and autoimmunity will be highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available